Recovery Report: MetroPCS Wireless Inc.'s Proposed $1.5 Billion Secured Bank Facilities Oct 06

  • ID: 1872840
  • October 2006
  • Standard & Poors

On Oct. 9, 2006, Standard & Poor's Ratings Services assigned its 'B' rating to intermediate holding company MetroPCS Wireless Inc.'s proposed $1.5 billion of new secured bank loan facilities. The rating is one notch above the corporate credit rating of Dallas-based parent company MetroPCS Communications Inc. (MetroPCS). A recovery rating of '1' was also assigned, indicating prospects for full recovery of principal in the event of a payment default. These ratings are based on preliminary information and subject to receipt and review of the final bank loan documents. The facilities consist of a seven year $1.4 billion term loan B facility and a five-year $100 million revolving credit. Proceeds from these bank facilities, coupled with the issuance of $1.1 billion...

Companies mentioned in this report are: MetroPCS Communications Inc.,MetroPCS Wireless Inc.

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Full Analysis

Note: Product cover images may vary from those shown

MetroPCS Communications Inc.,MetroPCS Wireless Inc.

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer, Inc.